Biosimilars in practice: building confidence through science and education

Access grows when science earns trust. Biosimilars — highly similar versions of approved biological medicines — expand treatment access across immunology, oncology, diabetes care and beyond. Europe’s experience is the world’s deepest, and its scientific position is clear: the European Medicines Agency and the Heads of Medicines Agencies have jointly confirmed that biosimilars approved in the EU are interchangeable with their reference medicine or an equivalent biosimilar, grounded in extensive comparative evidence and years of safety experience.^[1]

Why confidence needs cultivation

Approval science and bedside comfort are different things. Clinicians reasonably ask how similarity is demonstrated; patients notice a new name on a familiar therapy. Confidence grows through education rather than assertion:

• Understand the paradigm. Biosimilar development inverts the usual logic: an exhaustive analytical comparison carries the weight, confirmed by clinical data — a rigorous pathway designed for molecules whose reference is already deeply characterised.
• Communicate switching well. Clear, positive explanation at the point of change preserves the therapeutic relationship and adherence.
• Track and share experience. Local outcomes data, discussed openly, turns policy into lived confidence.
• Align the team. Pharmacists, prescribers and nurses telling one consistent story matter more than any leaflet.

The bigger picture

Every well-managed biosimilar programme frees resources that health systems reinvest in care — a quiet, compounding contribution to sustainability that professionals can be genuinely proud to lead.

Two decades of accumulated proof

Europe wrote the world’s first biosimilar rulebook, establishing its regulatory pathway in the mid-2000s and approving the first biosimilar — a growth hormone — in 2006. What followed is one of regulatory science’s quiet success stories: approvals accumulating across ever more complex molecule classes, from growth factors to monoclonal antibodies, alongside years of pharmacovigilance experience in which biosimilars have behaved as their scientific assessment predicted. That record is why European regulators were ultimately able to state jointly that biosimilars approved in the EU are interchangeable with their reference products — a statement resting not on hope but on the deepest experience base any region possesses.

The economics compound the science. Biologics rank among medicine’s most transformative and most expensive therapies; competition from biosimilars has saved European health systems substantial sums and — more importantly — widened patient access, letting clinicians treat earlier and more broadly within the same budgets.

Why confidence still needs building

• The nocebo shadow. When a switch is framed hesitantly, patients can experience genuine worsening unrelated to the molecule — communication quality is, literally, a clinical variable.
• Education gaps travel. Clinicians trained before the biosimilar era may carry outdated caution; structured education consistently shifts both confidence and prescribing.
• Terminology confusion. Biosimilars are not generics — and explaining the “totality of evidence” approach, where analytical comparability does the heavy lifting, requires deliberate teaching.
• Implementation is local. Switch programmes with clear protocols, patient information and pharmacist involvement succeed; unmanaged switches breed the anxiety they ignore.

Looking ahead

A significant wave of biologic patent expiries will bring biosimilar competition to new therapy areas in the coming years, and health systems are steadily moving from cautious adoption to strategic use — building savings into access programmes and treating biosimilar literacy as core professional knowledge. The lesson of the European experience generalises: scientific rigour plus patient communication plus professional education is the formula that converts regulatory approval into real-world benefit.

Where EUSTM fits

The EUSTM Academy’s Professional Certification in Regulatory Affairs (PCRA) covers the approval science, while the Professional Certification in Market Access & Pricing (PCMAP) addresses the adoption and sustainability dimension of biological therapy programmes.

Disclaimer. This Expert Insight is provided by EUSTM for general informational and educational purposes only. It does not constitute medical, clinical, legal, regulatory or other professional advice, and it should not be relied upon as the basis for clinical, regulatory or business decisions. While care is taken in preparing this content, EUSTM makes no representation or warranty as to the accuracy, completeness or currency of any scientific, medical or other statements, and accepts no liability arising from the use of this content. Readers should consult the cited sources, the current official guidance of the relevant authorities and frameworks, and appropriately qualified professionals in their own jurisdiction. References to third-party organisations, publications or frameworks are for information only and do not imply affiliation or endorsement.

← All Expert Insights